Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 14, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Journal: European journal of haematology
Published: February 12, 2020
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: October 09, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.
Journal: Blood cancer journal
Published: August 10, 2018
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France.
Journal: Advances in hematology
Published: April 06, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: January 06, 2018
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Journal: American journal of hematology
Published: October 12, 2017
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 20, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies.
Journal: Journal of geriatric oncology
Published: May 01, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Journal: British journal of haematology
Published: July 15, 2016
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.
Journal: Science translational medicine
Published: May 18, 2016
Last Updated: 09/26/2026